Mark Martinez, MD
Pulmonary Disease · Salt Lake City, UTNPI 1508861964
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 2 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. That places this record below the midpoint for pulmonary disease clinicians in UT, where the typical reported total is $297.
Across 2 payments — averaging $14.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$17
- Merck$13
Across 48 payments — averaging $5428.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$133K
- AstraZeneca$89K
- Insmed, Inc.$21K
- Mylan Specialty L.p.$18K
What the payments were for
- Food & beverage$29100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 1 | $17 |
| Merck | 1 | $13 |
How this compares
$29 in reported general payments places this provider in the 20th percentile of 101 pulmonary disease providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 292 | $88,071 |
| Norditropin FlexproSomatropin | 12 | $66,975 |
| Sevelamer Carbonate | 35 | $24,006 |
| Budesonide | 118 | $19,582 |
| Potassium Chloride | 214 | $18,598 |
| XareltoRivaroxaban | 65 | $17,071 |
| FanaptIloperidone | 23 | $15,439 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 55 | $14,002 |
| LinzessLinaclotide | 22 | $12,646 |
| Levetiracetam | 238 | $12,129 |
| MyrbetriqMirabegron | 50 | $12,095 |
| Atrovent HfaIpratropium Bromide | 24 | $12,030 |
| Ipratropium-AlbuterolIpratropium/Albuterol Sulfate | 240 | $8,355 |
| Meropenem-0.9% NaclMeropenem-0.9% Sodium Chloride | 24 | $8,197 |
| JardianceEmpagliflozin | 24 | $7,664 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $17 | $12,09550 claims |
| MerckJanuvia, Dulera | $13 | $10,57337 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 101 pulmonary disease providers in Utah.
Other pulmonary disease in Salt Lake City
- Mary ScholandSalt Lake City$325K
- Chakravarthy ReddySalt Lake City$82K
- James PearlSalt Lake City$69K
- Jefferson ChambersSalt Lake City$57K
- Lara HardmanSalt Lake City$37K
- Charles ElliottSalt Lake City$12K
- Jacqueline ChoaSalt Lake City$9K
- Ann JefferdsSalt Lake City$9K
- Erin BlackstockSalt Lake City$7K
- Michael BourneSalt Lake City$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.